Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Biocryst Pharmaceuticals (BCRX) stock in plain English

Free brief · no signupStart here
BCRXPublished Nov 17, 2026
Biocryst Pharmaceuticals Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells Orladeyo, an oral daily pill that prevents attacks of hereditary angioedema. Develops and commercializes other targeted enzyme inhibitors for rare complement system disorders.
Assets:
Orladeyo franchiseGenerates the vast majority of commercial product revenue globally
Durham research labsDiscovery laboratories and headquarters based in North Carolina
Complement pipelineClinical development stage testing oral Factor D inhibitors
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
+0.27%$7.32
$1.88B
n/a (loss)
$960.93M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BCRX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Biocryst Pharmaceuticals (BCRX) do?

Biocryst Pharmaceuticals Inc (BCRX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells Orladeyo, an oral daily pill that prevents attacks of hereditary angioedema. Develops and commercializes other targeted enzyme inhibitors for rare complement system disorders. BioCryst designs and commercializes oral small molecule medicines for rare genetic and enzyme mediated diseases. It is worth $1.88B on the market and sold $960.93M over the last year.

Market cap
$1.88B
P/E ratio
None (reported a loss)
Annual sales
$960.93M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 17, 2026

Brands and businesses behind BCRX

  • Orladeyo: A daily prescription capsule that prevents hereditary angioedema attacks, earning revenue through specialty pharmacy sales.
  • Rapivab: An emergency intravenous influenza treatment sold to hospitals and government stockpiles.

BCRX’s flags, in plain English

Each flag is a number from Biocryst Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Wide Gross Margin

Gross margin of 97.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 117.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Cheap on Cash Flow

Priced at 5.4 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Burning Cash

Losing money, profit margin of -37.4%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about BCRX

How big is Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’ market cap is $1.88B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $960.93M: what customers paid the company over the last year, before any costs.

What is BCRX’s P/E ratio?

BCRX has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with BCRX?

Revenue depends almost entirely on a single commercial drug, making cash flow vulnerable to rival treatments. That is one risk on Biocryst Pharmaceuticals’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Biocryst Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BCRX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card